These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29881820)

  • 21. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
    Bowlus CL; Pockros PJ; Kremer AE; Parés A; Forman LM; Drenth JPH; Ryder SD; Terracciano L; Jin Y; Liberman A; Pencek R; Iloeje U; MacConell L; Bedossa P
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1170-1178.e6. PubMed ID: 31606455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel.
    Pate J; Gutierrez JA; Frenette CT; Goel A; Kumar S; Manch RA; Mena EA; Pockros PJ; Satapathy SK; Yimam KK; Gish RG
    BMJ Open Gastroenterol; 2019; 6(1):e000256. PubMed ID: 30815273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
    De Vincentis A; D'Amato D; Cristoferi L; Gerussi A; Malinverno F; Lleo A; Colapietro F; Marra F; Galli A; Fiorini C; Coco B; Brunetto M; Niro GA; Cotugno R; Saitta C; Cozzolongo R; Losito F; Giannini EG; Labanca S; Marzioni M; Marconi G; Morgando A; Pellicano R; Vanni E; Cazzagon N; Floreani A; Chessa L; Morelli O; Muratori L; Pellicelli A; Pompili M; Ponziani F; Tortora A; Rosina F; Russello M; Cannavò M; Simone L; Storato S; Viganò M; Abenavoli L; D'Antò M; De Gasperi E; Distefano M; Scifo G; Zolfino T; Calvaruso V; Cuccorese G; Palitti VP; Sacco R; Bertino G; Frazzetto E; Alvaro D; Mulinacci G; Palermo A; Scaravaglio M; Terracciani F; Galati G; Ronca V; Zuin M; Claar E; Izzi A; Picardi A; Invernizzi P; Vespasiani-Gentilucci U; Carbone M;
    Liver Int; 2022 Nov; 42(11):2453-2465. PubMed ID: 35932095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.
    Bowlus CL
    Hepat Med; 2016; 8():89-95. PubMed ID: 27621676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
    Gazda J; Drazilova S; Gazda M; Janicko M; Koky T; Macej M; Carbone M; Jarcuska P
    Dig Liver Dis; 2023 Oct; 55(10):1318-1327. PubMed ID: 36593158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.
    Carbone M; Sharp SJ; Flack S; Paximadas D; Spiess K; Adgey C; Griffiths L; Lim R; Trembling P; Williamson K; Wareham NJ; Aldersley M; Bathgate A; Burroughs AK; Heneghan MA; Neuberger JM; Thorburn D; Hirschfield GM; Cordell HJ; Alexander GJ; Jones DE; Sandford RN; Mells GF;
    Hepatology; 2016 Mar; 63(3):930-50. PubMed ID: 26223498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis.
    Gao Y; Li L; Li B; Zhan Y
    Can J Gastroenterol Hepatol; 2021; 2021():8829510. PubMed ID: 33511089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland.
    Terziroli Beretta-Piccoli B; Stirnimann G; Cerny A; Semela D; Hessler R; Helbling B; Stickel F; Kalid-de Bakker C; Bihl F; Giostra E; Filipowicz Sinnreich M; Oneta C; Baserga A; Invernizzi P; Carbone M; Mertens J
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):295-306. PubMed ID: 29181702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio.
    Yoo JJ; Cho EJ; Lee B; Kim SG; Kim YS; Lee YB; Lee JH; Yu SJ; Kim YJ; Yoon JH
    Gut Liver; 2018 Nov; 12(6):714-721. PubMed ID: 30400732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V; Kowdley KV
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.
    Webb GJ; Rana A; Hodson J; Akhtar MZ; Ferguson JW; Neuberger JM; Vierling JM; Hirschfield GM
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):278-287.e7. PubMed ID: 28993258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
    Kowdley KV; Luketic V; Chapman R; Hirschfield GM; Poupon R; Schramm C; Vincent C; Rust C; Parés A; Mason A; Marschall HU; Shapiro D; Adorini L; Sciacca C; Beecher-Jones T; Böhm O; Pencek R; Jones D;
    Hepatology; 2018 May; 67(5):1890-1902. PubMed ID: 29023915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and promising therapy for primary biliary cholangitis.
    Gossard AA; Lindor KD
    Expert Opin Pharmacother; 2019 Jun; 20(9):1161-1167. PubMed ID: 30931642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Obeticholic acid in primary biliary cholangitis : PBC OCA international study of efficacy (POISE)].
    Gerken G; Nitschmann S
    Internist (Berl); 2017 Feb; 58(2):202-204. PubMed ID: 28116470
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.